Sunday, December 21, 2014

Amarantus posts positive preclinical data for retinitis pigmentosa

Amarantus posts positive preclinical data for retinitis pigmentosa

November 25, 2014 by · Leave a Comment 

Tweet Amarantus BioScience Holdings (OTCQB:AMBS) has announced positive effects of Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) for the protection from vision loss in an animal model of retinitis pigmentosa (RP). A single intravitreal administration of MANF after the onset of retinal degeneration on day 31 resulted in a statistically significant protective effect on visual acuity on day […]

Tandem Diabetes in data partnership with Tidepool

Tandem Diabetes in data partnership with Tidepool

November 21, 2014 by · Leave a Comment 

Tweet Tandem Diabetes Care (NASDAQ:TNDM) has entered into a partnership with Tidepool, a non-profit dedicated to improving diabetes therapy management by offering an open source software platform that increases diabetes data accessibility. The accord will enable users of the Tidepool Platform, which is currently under development, to download and access data from Tandem’s t:slim Insulin […]

Tandem takes consumer device approach to insulin pumps

Tandem takes consumer device approach to insulin pumps

November 18, 2014 by · Leave a Comment 

http://www.youtube.com/watch?v=qMfQNC0MqbI&list=PLaVPFQzKqgRmCoJ4T6oNF7v3EWcnDCobu’]

Tweet Tandem Diabetes (NASDAQ:TNDM), which now markets the popular t:slim Insulin Pump for people with Type 1 diabetes and has two new pumps awaiting FDA clearance, has taken a unique consumer-focused approach to the design of its products. “When we started the company, we had to figure out why only 27% of people with Type […]

rEVO Biologics spearheading preeclampsia treatment

rEVO Biologics spearheading preeclampsia treatment

November 11, 2014 by · Leave a Comment 

Tweet Closely held rEVO Biologics is enrolling patients in a Phase 3 clinical trial of its ATryn recombinant human antithrombin for the treatment of early-onset preeclampsia, with top-line data expected in the second quarter of 2016. “This is a potentially life threatening disorder of pregnancy and a devastating unmet medical need,” Yann Echelard, president and […]

Stifel starts Vitae Pharma at buy

Stifel starts Vitae Pharma at buy

October 20, 2014 by · Leave a Comment 

Tweet Stifel has initiated coverage of Vitae Pharmaceuticals (NASDAQ:VTAE) with a “buy” rating and price target of $14. The stock closed at $6.30 on Friday. “Vitae’s unique technology platform encompasses the unique ability to rationally design clinical candidates and represents the principal competitive advantage of the company,” writes analyst Dr. Brian Klein. He said Vitae’s CONTOUR […]

Dipexium aims to have first topical antibiotic approved for DFI

Dipexium aims to have first topical antibiotic approved for DFI

September 2, 2014 by · Leave a Comment 

Tweet Dipexium (NASDAQ:DPRX) is enrolling patients in two pivotal Phase 3 trials of its Locilex topical antibiotic in what it hopes will be the first FDA-approved antibiotic topical cream for the treatment of mild infections of diabetic foot ulcers. “Current treatments used off-label to treat mild diabetic foot infections (DFI) generate systemic resistance, exhibit poor […]

WB starts Tandem Diabetes Care at outperform

WB starts Tandem Diabetes Care at outperform

July 15, 2014 by · Leave a Comment 

Tweet William Blair has initiated coverage of Tandem Diabetes Care (NASDAQ:TNDM) with an “outperform” rating and “aggressive growth” profile. The stock closed at $13.37 on Tuesday. Tandem Diabetes makes and markets a durable, tube-based insulin pump with an easy to train and use touch screen user interface to treat Type 1 and potentially Type 2 […]

HCW starts Transition Therapeutics at buy

HCW starts Transition Therapeutics at buy

July 15, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) with a “buy” rating and 12-month price target of $10. The stock closed at $6.58 on Monday. Transition has two molecules in clinical evaluation in three indications. ELND005 is a small molecule in Phase 2 for Alzheimer’s disease (AD) associated agitation, and Down syndrome […]

Pivotal’s fight against fat gains media exposure

Pivotal’s fight against fat gains media exposure

June 25, 2014 by · Leave a Comment 

Tweet The latest issue of Bio Business magazine includes an article about the global obesity epidemic that highlights the efforts of Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to tackle the problem by focusing on the development of Omega-3 therapies and diagnostics. “The consequences of an Omega-3 deficiency could be obesity, diabetes, elevated triglycerides, high cholesterol and coronary heart […]

Transition, Lilly begin Phase 2 diabetes study

Transition, Lilly begin Phase 2 diabetes study

May 15, 2014 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) announced the dosing of the first patient in a Phase 2 clinical study of TT-401, a drug candidate for the treatment of Type 2 diabetes. The study is expected to enroll up to 375 Type 2 diabetes subjects and will be performed by Transition’s development partner, Eli Lilly (NYSE:LLY). The objectives […]

Next Page »

Email Newsletters with Constant Contact
Google+